ProCE Banner Activity

CME

Clinical Advances in Immune Thrombocytopenia: Integrating New Therapies

Multimedia
In this interactive on-demand Webcast from a live CCO Webinar, an expert panel discusses best practices and emerging strategies in managing patients with ITP.

Physicians: Maximum of 2.50 AMA PRA Category 1 Credits

Released: December 09, 2020

Expiration: December 08, 2021

No longer available for credit.

Share

Faculty

David J. Kuter

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Keith R. McCrae

Keith R. McCrae, MD

Professor, Medicine/Hematology/Oncology
Case Western Reserve University School of Medicine
Cleveland, Ohio

Michael Tarantino

Michael Tarantino, MD

Chief Medical Officer
Chief Executive Officer and President

The Bleeding & Clotting Disorders Institute
Professor of Pediatrics and Medicine
University of Illinois College of Medicine at Peoria
Peoria, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Dova Pharmaceuticals

Target Audience

This program is intended for hematologists and other clinicians involved in the management of patients with immune thrombocytopenia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify treatment-naive patients with ITP who would benefit from intensified therapy to enhance remission rates
  • Plan individualized second-line treatment regimens for ITP that is unresponsive to traditional steroids and splenectomy
  • Select optimal therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist
  • Evaluate therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, athletes, military, first responders, or those with chronic liver disease or undergoing a planned medical procedure
  • Discuss the available data and ongoing clinical trials investigating novel agents and combination regimens for the treatment of ITP

Program Director Disclosure

Program Director

David J. Kuter, MD, DPhil

Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

David J. Kuter MD, DPhil, has disclosed that he has received funds for research support from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Immunovant, Kezar, Principia, Protalex, Rigel, Takeda (Bioverativ) and consulting fees from Actelion (Syntimmune), Agios, Alnylam, Amgen, Argenx, Bristol-Myers Squibb, Caremark, CRICO, Daiichi Sankyo, Dova, Genzyme, Immunovant, Incyte, Kyowa-Kirin, Merck Sharp & Dohme, Momenta, Novartis, Pfizer, Platelet Disorder Support Association, Principia, Protalex, Protalix, Rigel, Sanofi, Genzyme, Shionogi, Shire, Takeda (Bioverativ), UCB, and Zafgen.

Faculty Disclosure

Primary Author

Keith R. McCrae, MD

Professor, Medicine/Hematology/Oncology
Case Western Reserve University School of Medicine
Cleveland, Ohio

Keith R. McCrae, MD, has disclosed that he has received consulting fees from Dova, Novartis, and Rigel.

Michael Tarantino, MD

Chief Medical Officer
Chief Executive Officer and President

The Bleeding & Clotting Disorders Institute
Professor of Pediatrics and Medicine
University of Illinois College of Medicine at Peoria
Peoria, Illinois

Michael Tarantino, MD, has disclosed that he has received consulting fees from Amgen, Biomarin, Genentech, Grifols, Magellan, Octapharma, Principia, and Takeda and funds for research support from Takeda.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer reports that his spouse has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 09, 2020, through December 08, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners in using new and emerging therapeutic options for patients with ITP.